PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer

This publication has 11 references indexed in Scilit:

• Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
  Published by Elsevier ,2003
• In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin
  Gene Therapy, 2003
• Cancer Statistics, 2003
  CA: A Cancer Journal for Clinicians, 2003
• Role of PI3K Signaling in Survival and Progression of LNCaP Prostate Cancer Cells to the Androgen Refractory State
  Endocrinology, 2001
• PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression
  Journal of Biological Chemistry, 2001
• Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
  Oncogene, 2001
• Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis
  Published by Elsevier ,2001
• MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells
  Oncogene, 2000
• Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
  Nature Genetics, 1997
• PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
  Science, 1997